Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) announced this morning that the company has acquired a 20% ownership interest in softgel manufacturing and development company Capcium Inc. in exchange for a $10 million dollar investment into the company.
Capcium, is a privately-owned softgel manufacturing company located in Canada. Capcium specializes in the production of high-precision dosage controlled softgels containing cannabinoids. The company has extensive experience in pharmaceuticals and encapsulation.
Capcium will be using the $10 million dollar investment to expand the companies operations and is expected to construct a state-of-the-art product development and manufacturing facility that will be completed in Q4 2019. The facility will help streamline manufacturing time and will be located by Aurora’s manufacturing operation in Quebec.
Aurora Cannabis CEO Terry Booth gave this statement in the press release:
“This investment in Capcium reflects our strategic objective to further expand our differentiated, higher-margin product offerings. Capcium’s extensive know-how has enabled it to develop an advanced technology for the high-volume production of cannabis-based softgels.”